Tumor necrosis factor inhibitors in psoriasis: an update

Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA)....

Full description

Saved in:
Bibliographic Details
Published inSeminars in cutaneous medicine and surgery Vol. 33; no. 2 Suppl 2; p. S31
Main Authors Kerdel, Francisco A, Strober, Bruce E
Format Journal Article
LanguageEnglish
Published United States 01.03.2014
Subjects
Adalimumab
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Certolizumab Pegol
Etanercept
Humans
Immunoglobulin Fab Fragments - therapeutic use
Immunoglobulin G - therapeutic use
Infliximab
Polyethylene Glycols - therapeutic use
Psoriasis - drug therapy
Receptors, Tumor Necrosis Factor - therapeutic use
Tumor Necrosis Factors - antagonists & inhibitors
psoriasis treatment
Immunogenicity
TNF
tumor necrosis factor inhibitors
Online AccessGet more information

Cover

More Information
Summary:Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.
ISSN:1085-5629
DOI:10.12788/j.sder.0070